JS InnoPharm nets nearly RMB100m in financing round led by Ming Bioventures

JS InnoPharm announced the completion of nearly 100 million yuan in its Series A+ round of financing, which was led by Ming Bioventures and participated by Efung Capital, SIDVC, Zhidao Capital and Oriental Fortune Capital.

JS InnoPharm announced the completion of nearly 100 million yuan in its Series A+ round of financing, which was led by Ming Bioventures and participated by Efung Capital, SIDVC, Zhidao Capital and Oriental Fortune Capital.

Proceeds from this round of financing will be mainly used to promote the JES-1187 ERK kinase inhibitor JSI-1187 to carry out phase I clinical trials and establish a research and development pipeline centered on anti-tumor new drugs.

JS InnoPharm had secured a Series A financing round led by Biotrack Capital in 2018.

JS InnoPharm is located in Shanghai, focusing on the research and development of small molecule original anti-cancer drugs. The company adopts the “two-wheel drive” business model of independent research and development and project introduction, which accelerates the establishment of the research and development pipeline.

The company’s R&D team timely applied the latest discovery of the mechanism of action of internationally renowned clinical experts to develop the world’s first anti-cancer drug research and development, and strive to solve the highly unmet clinical needs of cancer patients at home and abroad.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/17/js-innopharm-nets-nearly-rmb100m-in-financing-round-led-by-ming-bioventures/.

Leave a Reply

Please Login to Comment